Tempus AI, Inc Share Price

Equities

TEM

US88023B1035

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 14:43:37 16/07/2024 BST 5-day change 1st Jan Change
38.23 USD +4.45% Intraday chart for Tempus AI, Inc +10.24% 0.00%
Sales 2024 * 690M 53.32B Sales 2025 * 922M 71.21B Capitalization 6.03B 466B
Net income 2024 * -747M -57.69B Net income 2025 * -231M -17.84B EV / Sales 2024 * 8.6 x
Net cash position 2024 * 96.84M 7.48B Net cash position 2025 * 77.19M 5.96B EV / Sales 2025 * 6.46 x
P/E ratio 2024 *
-7.95 x
P/E ratio 2025 *
-26.6 x
Employees 1,500
Yield 2024 *
-
Yield 2025 *
-
Free-Float 42.71%
More Fundamentals * Assessed data
Dynamic Chart
1 day+4.45%
1 week+10.24%
Current month+4.57%
1 month-9.07%
More quotes
1 week
34.45
Extreme 34.45
41.78
1 month
22.89
Extreme 22.89
43.00
Current year
22.89
Extreme 22.89
43.88
1 year
22.89
Extreme 22.89
43.88
3 years
22.89
Extreme 22.89
43.88
5 years
22.89
Extreme 22.89
43.88
10 years
22.89
Extreme 22.89
43.88
More quotes
Date Price Change Volume
15/07/24 36.6 -7.92% 1 039 671
12/07/24 39.76 +6.03% 1,633,543
11/07/24 37.5 +7.14% 982,889
10/07/24 35 +1.45% 1,079,337
09/07/24 34.5 +3.92% 2,065,089

Delayed Quote Nasdaq, July 15, 2024 at 09:00 pm

More quotes
Tempus AI, Inc. is a technology company. The Company provides next generation diagnostics across multiple disease areas, with technology capabilities, harnessing the data and analytics to help personalize medicine. The Company’s product lines include genomics, data, and artificial intelligence applications (AI). Its genomics product line leverages its laboratories to provide next generation sequencing, diagnostics, polymerase chain reaction (PCR), profiling, molecular genotyping, and other anatomic and molecular pathology testing. The Company's AI applications are focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools. Its primary product of AI applications is Next, an AI platform that leverages machine learning to apply an intelligent layer onto routinely generated data to proactively identify and minimize care gaps for oncology and cardiology patients.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
36.6 USD
Average target price
46 USD
Spread / Average Target
+25.68%
Consensus